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A B S T R A C T 
Objective: To study the efficacy and safety of 
single intra-articular injection of 6-mL hylan G-F 
20 in Chinese patients with symptomatic knee 
osteoarthritis. 
Design: Prospective case series.
Setting: Six government hospitals in Hong Kong.
Patients: Patients with primary knee osteoarthritis 
were recruited from six government hospitals from 
1 October 2010 to 31 May 2012. All patients received 
6-mL intra-articular injection of hylan G-F 20. 
Main outcome measures: Pain visual analogue 
scale, functional visual analogue scale, and 5-point 
Likert scale on change of pain and function were 
assessed. Adverse events were checked. Radiographs 
were taken pre-injection and at 3 months and 1 year.
Results: A total of 110 knees of 95 patients 
with primary knee osteoarthritis were treated. 
The mean age of the patients was 62 (standard 
deviation, 9.8) years. All patients completed 1 year 
of follow-up. The mean pain visual analogue scale, 
functional visual analogue scale, and Likert value 
for pain and function showed statistically significant 
improvements at 6 weeks, 3 months, 6 months, and 
1 year compared with the pre-injection values. No 
significant correlations were found between changes 
in visual analogue scale and age, body mass index, 
pre-injection radiological osteoarthritis severity, 
serum erythrocyte sedimentation rate, or C-reactive 
Efficacy and safety of hylan G-F 20 injection 
in treatment of knee osteoarthritis in Chinese 
patients: results of a prospective, multicentre, 
longitudinal study
Introduction
Osteoarthritis (OA) is a progressive degenerative 
joint disease initiated by multiple aetiological 
factors. When clinically evident, OA is characterised 
by joint pain, tenderness, stiffness, crepitus, effusion, 
and variable degrees of inflammation without 
New knowledge added by this study
• This study demonstrated that hylan G-F 20 is effective and safe to treat knee osteoarthritis in Chinese patients. 
Past studies were only conducted in Caucasian or mixed populations.
Implications for clinical practice or policy
• Viscosupplementation could be a valid option for managing patients with chronic and symptomatic knee 
osteoarthritis. Single injection preparation is safe and effective. Injection can be performed in an out-patient 
setting.
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systemic effects. Knee OA is a leading musculoskeletal 
cause of disability in elderly people around the 
world, and affects both Caucasian and Chinese 
populations.1-3 The burden of disease dramatically 
impacts health care costs. A local study found that, 
excluding joint replacement, the direct costs of 
ORIGINAL ARTICLECME
protein. Serial radiographs did not show any changes 
in the radiological severity of knee osteoarthritis. 
Overall, 16.4% of the patients experienced mild and 
self-limiting adverse events. 
Conclusion: Hylan G-F 20 is a safe and effective 
therapy to relieve pain and improve function for up 
to 1 year in Chinese patients with knee osteoarthritis.
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注射hylan G-F 20治療華籍患者膝關節骨性關節
炎的功效和安全性：前瞻性、縱向多中心研究
忻振凱、陳偉霖、袁偉康、容樹恆、葉啟源、范智豪、曲廣運
目的：研究替膝關節骨性關節炎華籍患者在關節內注射6毫升hylan 
G-F 20的功效和安全性。
設計：前瞻性病例系列研究。
安排：香港六間公立醫院。
患者：於2010年10月1日至2012年5月31日期間曾到六間公立醫院的
原發性膝關節骨性關節炎患者均被列入研究範圍。所有患者接受在關
節內注射6毫升hylan G-F 20。
主要結果測量：疼痛視覺模擬評分、功能性視覺模擬評分，以及5點
李克特量表上的疼痛和功能變化；是否有不良事件，以及於注射前、
注射後三個月和一年替患者進行的X光檢查。
結果：研究對象為95名（110例）原發性膝關節骨性關節炎患者，他
們平均年齡62歲（標準差9.8歲）。所有患者均完成一年隨訪。與注
射前比較，患者在注射後第六週、三個月、六個月和一年的疼痛視覺
模擬評分、功能性視覺模擬評分和5點李克特量表的平均分在統計學
上均有顯著改善。視覺模擬評分的改變與以下各項沒有顯著相關性：
患者年齡、身體質量指數、注射前放射性骨關節炎的嚴重程度、血紅
細胞沉降率或C反應蛋白。連續的放射照片亦沒有顯示膝關節骨性關
節炎重度有任何變化。16.4%患者出現輕微和自限性不良事件。
結論：替膝關節骨性關節炎華籍患者注射hylan G-F 20能安全而有效
地減輕疼痛和改善膝關節功能，療效可維持長達一年。
managing OA ranged from HK$11 690 to $40 180 
per person per year and indirect costs ranged from 
HK$3300 to $6640.4 
 There are many types of treatment for knee 
OA. These therapies can be divided into two major 
groups of non-surgical and surgical. Non-surgical 
therapies include exercise, weight loss, physical 
therapy, occupational therapy, medications (eg 
paracetamol, non-steroidal anti-inflammatory 
agents), and intra-articular injections (steroids, 
viscosupplementation). Surgical therapies mainly 
entail osteotomy and arthroplasty.5
 Knee OA has been associated with a decrease 
in the elasticity and viscosity of the synovial 
fluid,6-8 which may alter the transmission of 
mechanical forces to the articular cartilage, 
possibly increasing its susceptibility to mechanical 
damage, or wear and tear. Viscosupplementation 
is an intra-articular therapeutic modality based 
on the physiological importance of hyaluronan in 
synovial joints. Its therapeutic goal is to restore the 
viscoelasticity of synovial hyaluronan, decrease pain, 
improve mobility, and restore the natural protective 
functions of hyaluronan in the joint. 
 Hylan G-F 20 is a cross-linked sodium 
hyaluronate with a high average molecular weight 
of 6 million daltons. Hylan G-F 20 is used in North 
America and Europe for the treatment of pain 
associated with knee OA. However, there are no 
data available in the literature on the clinical benefits 
of the viscosupplement in Chinese populations. 
Therefore, we carried out a prospective, multicentre, 
longitudinal study to investigate the efficacy and 
safety of hylan G-F 20 in the treatment of knee OA 
in local Chinese patients over a period of 1 year. 
Methods
The study protocol was approved by the Institutional 
Review Boards/Ethics Committees of all six 
participating centres in Hong Kong. The inclusion 
criteria were: Chinese patients with primary knee 
OA who fulfilled the diagnostic criteria of the 
American College of Rheumatology; knee pain 
visual analogue scale (VAS) score of >50 (range, 
0-100) and/or functional VAS score of >50 (0-100); 
and willingness to pay for the viscosupplementation 
and participate in the study. The exclusion criteria 
were: knee arthritis of other aetiologies; knee 
surgery or previous intra-articular injection in the 
knee within 1 year of the study; known allergy to 
chicken extracts; or unwillingness to pay for the 
viscosupplementation or participate in the study. 
Weight-bearing radiographs of the affected knee joint 
(standard anteroposterior and lateral views) were 
taken at the screening visit. Severity of knee OA in 
the tibiofemoral and patellofemoral compartments 
was classified according to the Kellgren-Lawrence 
(KL) system. The overall severity was defined as the 
highest KL grade in any of the compartments. We also 
documented the patients’ body mass index (BMI), 
and checked serum erythrocyte sedimentation rate 
(ESR) and C-reactive protein (CRP) level.
 Single intra-articular preparation of 6 mL of 
hylan G-F was injected into the patients’ knees in 
the out-patient clinic. Strict aseptic technique was 
adopted with skin disinfection and draping. The 
injection was administered through a direct lateral 
parapatellar approach. Knee joint aspiration was 
performed using a separate syringe before injection 
of the viscosupplement. After injection, the patients 
were allowed to resume normal activities, but were 
advised against vigorous exercise for 2 to 3 days. 
Ice therapy was recommended in case of transient 
increase in pain and swelling. Patients could continue 
with their routine analgesics on a pro re nata basis.
 All patients were followed up regularly at 6 
weeks, 3 months, 6 months, and 1 year. A telephone 
interview was conducted at 2 weeks to record any 
adverse events, if present. The severity of knee pain 
and knee function using 0-100 VAS scores (where 
0 represents ‘no pain’ or ‘normal function’) were 
documented at each visit. Any changes in knee 
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pain and functional limitations were charted using 
a 5-point Likert scale. Standard radiographs of the 
knee were repeated at 3 months and 1 year to detect 
any changes in radiological severity. 
 The change in pain and functional VAS scores 
before and after injection during each visit was 
compared using paired t test. Using correlation tests, 
we tried to find out the predictive factors (including 
age, sex, BMI, pre-injection KL grade, pre-injection 
pain VAS, ESR, and CRP) of favourable treatment 
response. All analyses were performed using the 
Statistical Package for the Social Sciences (Windows 
version 20.0; SPSS Inc, Chicago [IL], US). Statistical 
significance was assumed if the P value was <0.05. 
Results
A total of 110 knees of 95 patients (31 men and 
64 women) were recruited from six government 
hospitals in Hong Kong from 1 October 2010 to 
31 May 2012. There were 59 left knees and 51 right 
knees. All patients completed 1 year of follow-up. 
The mean (± standard deviation) age of the patients 
was 62.0 ± 9.8 (range, 33-86) years. The mean BMI 
was 27.7 ± 4.6 kg/m2 (range, 18.3-46.8 kg/m2). The 
mean ESR was 23.35 ± 14.00 mm/h (range, 2.00-
66.00 mm/h) and the mean CRP level was 1.3 ± 1.7 
mg/L (range, 0.1-7.1 mg/L). The youngest patient in 
the study was 33 years old. His BMI was 25.9 kg/m2. 
X-rays of his right knee showed KL grade 1 OA in 
the patellofemoral compartment and KL grade 2 OA 
in the tibiofemoral compartment. He denied any 
previous injury to his knee. 
 The mean pain and functional VAS scores are 
shown in Figures 1 and 2, respectively. There were 
statistically significant improvements in pain and 
functional VAS scores after injection at every follow-
up visit when compared with the pre-injection scores 
(paired t test, P<0.0001 for all). Significant differences 
were also found between the pain and functional 
VAS scores at 1 year and at 6 weeks (P<0.001 and 
P<0.01, respectively), 3 months (P<0.003 and P<0.01, 
respectively), and 6 months (P<0.01 for both). The 
score differences between 6 weeks, 3 months, and 6 
months were not significant.
 Likert values were coded as 1 to 5 with 3 being 
no change and 1 being much reduced. A sign test 
against a median of 3 and an alternate hypothesis 
that the sample median was less than 3 was used. 
Significant reductions in pain and functional 
limitations were found at 6 weeks (P<0.001 for both), 
3 months (P<0.001 for both), 6 months (P<0.001 for 
both), and 1 year (P<0.03 for both). The proportion of 
patients feeling reduced or much reduced pain was 
74% at 6 weeks, 75% at 3 months, 62% at 6 months, 
and 49% at 1 year. The proportion of patients feeling 
no change in pain level (when compared with pre-
injection level) was 23% at 6 weeks, 22% at 3 months, 
33% at 6 months, and 43% at 1 year. 
FIG 1.  Changes in pain visual analogue scale (VAS) scores 
The circles represent the means with the vertical lines 95% confidence intervals. 
There were significant decreases in VAS scores at 6 weeks, 3 months, 6 months, and 1 
year compared with pre-injection level (all P<0.0001)
FIG 2.  Changes in functional visual analogue scale (VAS) scores
The circles represent the means with the vertical lines 95% confidence intervals. 
There were significant decreases in VAS scores at 6 weeks, 3 months, 6 months, and 1 
year compared with pre-injection level (all P<0.0001)
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 Investigation of predictive factors of good 
clinical response did not demonstrate any significant 
correlation with age, BMI, pre-injection VAS, ESR, 
or CRP (Pearson’s tests). Sex (Welch’s t test) and pre-
injection KL grade (analysis of variance test) did not 
significantly affect the treatment response. 
 Overall, 37 knees had KL grade IV OA, 38 
had grade III OA, 30 had grade II OA, and five had 
grade I OA before injection. Radiographs showed 
no significant changes in KL OA grades at 3 months 
and 1 year. A total of 18 (16.4%) knees experienced 
adverse events, including pain (14 knees), swelling 
(2 knees), and warmth (2 knees). All of the adverse 
events were mild and self-limiting. No patients 
required hospital admission or extra clinic visits for 
these self-reported events. 
Discussion
The evidence in the literature is still inconclusive 
regarding the clinical and biological efficacy of 
viscosupplementation. The 2006 Cochrane review 
summarised the results of 76 randomised controlled 
trials (RCTs) comparing hyaluronic acid (HA) and 
various other treatment modalities.9 The authors 
concluded that viscosupplementation is an effective 
treatment for knee OA with beneficial effects on 
pain, function, and global assessment, especially at 
the 5- to 13-week post-injection period. Although 
the sample size restriction may preclude any 
definitive comment on the safety of the products, no 
major safety issues were detected. The 2nd edition 
of the American Academy of Orthopaedic Surgeons 
guideline on treatment of knee OA claimed that 
“we cannot recommend using HA for patients with 
symptomatic knee OA”.10 This recommendation is 
based on the fact that although meta-analyses of 
the Western Ontario and McMaster Universities 
Osteoarthritis Index (WOMAC) for pain, 
function, and stiffness subscale scores all found 
statistically significant treatment effects, none of the 
improvements met the minimum clinically important 
improvement thresholds. The latest Osteoarthritis 
Research Society International guideline for non-
surgical management of knee OA claimed that the 
recommendation for intra-articular HA injection 
was ‘uncertain’, because the inconsistent conclusions 
among the meta-analyses and conflicting results 
regarding HA’s safety influenced the panel votes.11 
One of the drawbacks of the meta-analyses and 
reviews is that they pooled the results of studies that 
investigated different viscosupplement formulations. 
These included low- and high-molecular-weight HA 
preparations of avian or bacterial origin. Hylan G-F 
20 is a cross-linked HA derivative of avian origin, 
with relatively high molecular weight (average, 6000 
kDa) and fluid rheological properties similar to those 
of knee synovial fluid of healthy young individuals. 
In a 26-week RCT, hylan G-F 20 single-injection 
formulation resulted in significant improvements 
in WOMAC pain score, observer-reported disease 
status, and patient-reported health status score.12 
 Our study is the first in Chinese patients to 
investigate the efficacy and safety of hylan G-F 
20. The results show that the single 6-mL intra-
articular injection could significantly improve pain 
and function in patients with primary knee OA. 
The beneficial effect could be sustained for up to 
6 months. The VAS scores increased again by the 
1-year follow-up visit, but the values were still 
significantly lower than the pre-injection levels. The 
5-point Likert scale also revealed that about 75% 
of patients had reduced pain at 3 months, 62% at 6 
months, and the percentage remained decreased at 
50% at the 1-year follow-up visit. 
 A total of 16.4% of patients experienced mild 
and self-limiting local adverse reactions. No pseudo-
septic reaction or severe acute inflammatory reaction 
was reported.13 The interview was conducted by 
telephone at 2 weeks after injection, and was partly 
carried out by research assistants or nurses. Some 
patients might have confused ‘additional/new 
pain over the injection site’ with ‘pre-existing OA 
pain’, which led to the higher self-reported adverse 
event incidence. There are reports on HA causing 
adverse reactions; the most common of which is an 
inflammatory reaction or flare at the injection site 
characterised by injection site pain and swelling.14-16 
Hypersensitivity reactions to HA or avian proteins 
are listed as contra-indications for use of many of the 
HA products. Many of the inflammatory responses 
appear to be due to the molecular structure of the 
HA, as naturally derived hyaluronan sources appear 
to be better tolerated than highly cross-linked 
hyaluronan.13,17,18 Leopold et al19 demonstrated 
increased frequency of acute local reaction to 
hylan G-F 20 in patients receiving more than one 
course of treatment. Recently a murine model study 
showed a single injection of hylan G-F 20 led to less 
inflammation and lower antibody reaction when 
compared with a three-shot series of injections. In 
our study, the 6-mL single injection preparation 
was used. This approach offers another advantage 
over a multiple-injection regimen as it reduces the 
number of consultations, therefore saves money and 
manpower in government hospitals with limited 
health care resources. 
 The serial knee radiographs in our study did not 
show any changes (either progression or regression) 
of the radiological severity of OA after hylan G-F 
20 injection. To date, there is no concrete evidence 
in the literature to support the disease-modifying 
effect of HA injection. The radiographic KL grading 
system may not be sensitive enough to detect minor 
changes in the articular cartilage. We also did not 
have a control group for comparison. In a magnetic 
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resonance imaging–based RCT on articular cartilage 
volume change after four courses of hylan G-F 20 
injection at 6-month intervals, the authors claimed 
that there was less cartilage loss in the treatment 
group at 24 months (2.7% over the medial tibial 
plateau and 2.6% over the lateral tibial plateau).20 
Whether these differences are clinically significant 
is doubtful, however. We could not find any specific 
factors predicting good clinical response in our 
patients. This could be due to the relatively small 
sample size and the heterogeneity of our patients. 
The pre-injection parameters we investigated may 
not be sufficiently sensitive to survive the analysis. 
 There are a few limitations to this study. The 
pain and functional VAS scores were used because we 
believe they are patient-reported outcome measures, 
which would better reflect the clinical efficacy from 
the patients’ perspectives. The VAS scores are also easy 
to use, especially in the setting of a multicentre study. 
We did not include parameters such as knee range of 
motion, walking tolerance, or other knee scores as 
they were not the primary objectives of our study. It 
is well known that the placebo effect may account for 
30% of the perceived benefits of medical treatment.21 
We could not ascertain how much of the pain relief 
and functional improvement were attributable to 
the true therapeutic effects of hylan G-F 20 in view 
of the nature of our study design. A prospective, 
blinded, RCT may be able to eliminate the potential 
confounding factors and information bias. Changes 
in other treatment modalities during the follow-up 
period were not compared because of the potential 
complexity. It is difficult to standardise conservative 
treatment in terms of oral medication and exercise 
therapy, simply because patients with advanced knee 
OA may need stronger analgesics. Patients would also 
have a high non-compliance rate if we forced them to 
follow a single regimen. We decided to let all patients 
carry on with their usual conservative management 
and asked them if there were any changes in the pain 
and functional VAS scores during each follow-up 
after the viscosupplement injection. 
Conclusion
This prospective, multicentre study showed that 
single intra-articular injection of 6-mL hylan G-F 
20 was effective in providing statistically significant 
pain relief and functional improvement up to 1 year 
in Chinese patients with primary knee OA. Although 
adverse events were not uncommon, all of them were 
mild and self-limiting. Viscosupplementation with 
hylan G-F 20 could be a safe and beneficial option in 
managing patients with knee OA.
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